ADC Therapeutics SA expected to post a loss of 90  cents a share - Earnings Preview

ADC Therapeutics SA

04/05/2021 18:54

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to report
results on May 6.
* The Epalinges, Vaud-based company is expected to report
revenue of $94.33 thousand, according to the mean estimate from
3 analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for ADC Therapeutics SA is
for a loss of 90 cents per share. 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for ADC
Therapeutics SA is $55​, about 56.6% above​ its last closing
price of $23.87. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.14       -0.38      -1.05     Missed  -173.9
 Sep. 30 2020  -0.83       -0.81      -0.77     Beat    4.9
 Jun. 30 2020  -0.65       -0.65      -0.73     Missed  -12.3​
 Mar. 31 2020              -0.67                        
 ​​            ​                                        ​
                                                        ​
 This summary was machine generated May 4 at 17:54 GMT.  All
figures in US dollars unless otherwise stated